XIAOMI-W
01810
BABA-W
09988
ALI HEALTH
00241
KUAISHOU-W
01024
BIDU-SW
09888
(Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | (Q6)Jun 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Turnover | 47.03%2.68B | 61.14%1.68B | 67.85%751.65M | 73.65%2.46B | 76.13%1.82B | 60.92%1.04B | 46.04%447.8M | 20.37%1.42B | 7.64%1.04B | -14.24%648.2M |
Operating income | 47.03%2.68B | 61.14%1.68B | 67.85%751.65M | 73.65%2.46B | 76.13%1.82B | 60.92%1.04B | 46.04%447.8M | 20.37%1.42B | 7.64%1.04B | -14.24%648.2M |
Cost of sales | -58.17%-433.53M | -47.97%-263.07M | -52.75%-124.94M | -32.62%-379.92M | -28.71%-274.09M | -30.33%-177.78M | -25.37%-81.79M | -73.72%-286.48M | -83.01%-212.95M | -97.84%-136.41M |
Operating expenses | -58.17%-433.53M | -47.97%-263.07M | -52.75%-124.94M | -32.62%-379.92M | -28.71%-274.09M | -30.33%-177.78M | -25.37%-81.79M | -73.72%-286.48M | -83.01%-212.95M | -97.84%-136.41M |
Gross profit | 45.06%2.25B | 63.85%1.42B | 71.23%626.72M | 84.06%2.08B | 88.40%1.55B | 69.07%865.28M | 51.63%366.01M | 11.67%1.13B | -2.73%822.87M | -25.49%511.79M |
Selling expenses | -21.73%-1.33B | -20.40%-871.16M | -30.12%-427.43M | -17.74%-1.5B | -14.83%-1.09B | -15.58%-723.53M | -11.52%-328.5M | -29.06%-1.28B | -38.80%-948.87M | -51.06%-625.98M |
Research and development expenses | -9.86%-1.41B | -10.07%-915.1M | -12.74%-460.64M | -8.42%-1.78B | -7.54%-1.28B | -8.23%-831.35M | -4.79%-408.58M | -12.42%-1.64B | -16.11%-1.19B | -13.49%-768.12M |
Depreciation and amortization | ---- | ---- | ---- | -366.05%-3.5M | ---- | 0.27%-375K | 0.53%-187K | -0.13%-751K | 0.00%-563K | -0.27%-376K |
Operating profit | 40.68%-488.77M | 46.59%-368.51M | 29.60%-261.35M | 32.52%-1.21B | 37.63%-823.94M | 21.83%-689.97M | 16.25%-371.26M | -24.39%-1.79B | -52.37%-1.32B | -118.12%-882.69M |
Financing income | -30.67%40.03M | -5.47%29.39M | 0.90%16.16M | 41.02%74.01M | --57.74M | 44.57%31.09M | 59.03%16.02M | --52.48M | ---- | 337.72%21.5M |
Special items of earning before tax | -99.62%1.1M | 77.54%-10.22M | -90.37%1.76M | 237.54%307.89M | 239.28%291.14M | 61.31%-45.52M | 52.95%18.3M | -1,507.52%-223.85M | -1,474.11%-209.03M | -2,257.72%-117.65M |
Earning before tax | 5.77%-447.65M | 50.41%-349.35M | 27.75%-243.43M | 57.89%-825.84M | 68.95%-475.06M | 28.04%-704.4M | 20.01%-336.94M | -36.32%-1.96B | -79.63%-1.53B | -133.78%-978.83M |
Tax | -15.77%-45.26M | 11.75%-22.21M | 32.79%-7.72M | -30.61%-55.87M | -37.61%-39.09M | -13.92%-25.17M | 17.61%-11.49M | -122.48%-42.78M | -85.02%-28.41M | -554.53%-22.09M |
After-tax profit from continuing operations | 4.13%-492.91M | 49.07%-371.56M | 27.92%-251.15M | 56.00%-881.71M | 67.01%-514.16M | 27.11%-729.57M | 19.94%-348.43M | -37.45%-2B | -79.73%-1.56B | -141.86%-1B |
Earning after tax | 4.13%-492.91M | 49.07%-371.56M | 27.92%-251.15M | 56.00%-881.71M | 67.01%-514.16M | 27.11%-729.57M | 19.94%-348.43M | -37.45%-2B | -79.73%-1.56B | -141.86%-1B |
Profit attributable to shareholders | 4.13%-492.91M | 49.07%-371.56M | 27.92%-251.15M | 56.00%-881.71M | 67.01%-514.16M | 27.11%-729.57M | 19.94%-348.43M | -37.45%-2B | -79.73%-1.56B | -141.86%-1B |
Basic earnings per share | 5.26%-0.36 | 50.00%-0.27 | 26.92%-0.19 | 56.38%-0.65 | 67.24%-0.38 | 28.00%-0.54 | 21.21%-0.26 | -23.14%-1.49 | -61.11%-1.16 | -114.29%-0.75 |
Diluted earnings per share | 5.26%-0.36 | 50.00%-0.27 | 26.92%-0.19 | 67.24%-0.38 | 28.00%-0.54 | 21.21%-0.26 | -61.11%-1.16 | -0.75 | ||
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | UAS | UAS | UAS | UAS | UAS | UAS | UAS | UAS | UAS | UAS |
Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | Unqualified Opinion | -- | -- |
Auditor | -- | -- | -- | Ernst & Young LLP | -- | -- | -- | Ernst & Young LLP | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.